Discovery of 1-pyrimidinyl-2-aryl-4,6-dihydropyrrolo [3,4-d]imidazole-5(1H)-carboxamide as a novel JNK inhibitor

Article abstract of DOI:10.3390/ijms21051698

We designed and synthesized 1-pyrimidinyl-2-aryl-4, 6-dihydropyrrolo [3,4-d] imidazole-5(1H)-carboxamide derivatives as selective inhibitors of c-Jun-N-terminal Kinase 3 (JNK3), a target for the treatment of neurodegenerative diseases. Based on the compounds found in previous studies, a novel scaffold was designed to improve pharmacokinetic characters and activity, and compound 18a, (R)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydro pyrrolo [3,4-d]imidazole-5(1H)-carboxamide, showed the highest IC₅₀ value of 2.69 nM. Kinase profiling results also showed high selectivity for JNK3 among 38 kinases, having mild activity against JNK2, RIPK3, and GSK3β, which also known to involve in neuronal apoptosis.

Full text of DOI:10.3390/ijms21051698

International Journal of
Molecular Sciences
Article
Discovery of
1-Pyrimidinyl-2-Aryl-4,6-Dihydropyrrolo
[3,4-d]Imidazole-5(1H)-Carboxamide as a Novel
JNK Inhibitor
Miyoung Jang, Youri Oh, Hyunwook Cho, Songyi Yang, Hyungwoo Moon, Daseul Im
and Jung-Mi Hah *
College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University,
Ansan 15588, Korea; sam4822@hanynag.ac.kr (M.J.); apdlzld4477@hanyang.ac.kr (Y.O.);
lod0201@hanyang.ac.kr (H.C.); y983727@naver.com (S.Y.); mhu91@naver.com (H.M.);
bestimda@hanyang.ac.kr (D.I.)
* Correspondence: jhah@hanyang.ac.kr; Tel.: +82-31-400-5803
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
ꢀꢁꢂꢃꢄꢅꢆ
Received: 29 January 2020; Accepted: 27 February 2020; Published: 2 March 2020
Abstract: We designed and synthesized 1-pyrimidinyl-2-aryl-4, 6-dihydropyrrolo [3,4-d]
imidazole-5(1H)-carboxamide derivatives as selective inhibitors of c-Jun-N-terminal
Kinase
Based on the compounds found in previous studies,
designed to improve pharmacokinetic characters and activity, and compound 18a
3
(JNK3),
a
target for the treatment of neurodegenerative diseases.
a
novel scaffold was
,
(R)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-
dihydro pyrrolo [3,4-d]imidazole-5(1H)-carboxamide, showed the highest IC50 value of 2.69 nM.
Kinase profiling results also showed high selectivity for JNK3 among 38 kinases, having mild activity
against JNK2, RIPK3, and GSK3β, which also known to involve in neuronal apoptosis.
Keywords: JNK; RIPK; imidazole; Alzheimer’s disease; SAR
1. Introduction
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases and features both
amyloid
β plaques and neurofibrillary tangles (NFTs) as pathological hallmarks [1]. Although the cause
of AD, which affects many, is not clearly identified, many therapeutic agents have been studied to inhibit
the formation of these two hallmarks, and we aim to develop a treatment for Alzheimer’s disease that
targets and inhibits JNK3, which is deeply involved in the formation of amyloid
The c-Jun N-terminal kinase (JNK), also called stress-activated protein kinase, is a protein kinase
that belongs to the mitogen-activated protein kinase (MAPK) family [ ]. JNKs are encoded by the
jnk1, jnk2, and jnk3 genes [ ], and there are approximately 10 isoforms with molecular weights of
β protein and NFT [2].
3
2
46–55 kDa, depending on splicing. The signaling system of JNKs is activated by UV rays, inflammatory
cytokines, and oxidative stress. The activated MKK4 and MKK7 phosphorylate the Thr183 and Tyr185
of JNKs. The activated JNKs promote the phosphorylation of proteins (AP-1, c-Jun, etc.) involved
in cell apoptosis, proliferation, and differentiation [
whereas JNK3 is mainly expressed in the brain [9–11].
Most importantly, JNK3 expressed in the brain phosphorylates Thr668 of the amyloid precursor
protein (APP), so that APP is located on the cell membrane and cleaved by -secretase and -secretase
to induce the formation of amyloid protein [12 13]. The produced amyloid protein is known to
4–8]. JNK1 and JNK2 are expressed in most cells,
β
γ
β
,
β
form amyloid plaques, causing neuronal cell apoptosis, and the amyloid
β
protein also causes positive
Int. J. Mol. Sci. 2020, 21, 1698; doi:10.3390/ijms21051698
www.mdpi.com/journal/ijms

Int. J. Mol. Sci. 2020, 21, 1698
2 of 17
feedback to reactivate JNK3 [12]. In addition, JNK3 phosphates Ser422 of the tau protein to form
NFTs. The formed NFTs disrupt the transport of neurotransmitters by breaking down the structure of
microfabrication in neurons, leading to the apoptosis of nerve cells [14].
We studied protein kinase inhibitors targeting JNK3 to develop effective treatments for Alzheimer’s
disease by impeding these mechanisms.
2. Results and Discussion
In previous studies [15], we discovered a 1-phenyl-2-pyrimidyl-1H-benzimidazole derivative,
a hit compound that has JNK3 inhibitory activity, especially excellent selectivity versus other protein
kinases. Therefore, we derivatized the hit compound further for better inhibitory activity on JNK3,
and the lead compound, 1-(2-aminopyrimidin-4-yl)-2-(naphthalen-2-yl)-1H-benzo[d]imidazol-6-ol,
was found. Moreover, we continued the efforts to improve the pharmacokinetic problem in the
previous scaffold, and also to increase the activity against JNK3, having identified the main interactions
through the docking study of the previous scaffold (hydrogen bonds in the hinge region, hydrophobic
interaction of the aromatic ring, and the hydrogen bond of phenol in the benzimidazole scaffold).
As a result, 1-pyrimidinyl-2-aryl-4, 6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide derivatives
were designed; these compounds had a five-membered ring, 2,5-dihydropyrrole, instead of the benzene
in the previous benzimidazole scaffold (Figure 1).
Figure 1. Docking structures of the previous c-Jun N-terminal kinase 3 (JNK3) inhibitor (PDB: 3OY1)
and design of the present 1-pyrimidinyl-2-aryl-4, 6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide
scaffold. The important pharmacophores have been colored in blue in previous scaffold and red in
present scaffold.
We proceeded with the synthesis of 1-pyrimidinyl-2-aryl-4, 6-dihydropyrrolo[3,4-d]
imidazole-5(1H)-carboxamide derivatives via Scheme 1. For the synthesis of the core structure,
dihydropyrrolo[3,4-d]imidazole-bicycle, we started to synthesize a 1,2-diaminopyrrolidine ring.
The commercially available 1, 4-dichlorobut-2-ene (1) and tert-butyl carbamate were reacted to form
Boc-pyrrolidine (2). The dihydroxylation using osmium tetroxide was performed to give diol (3), and it
was transformed to diazide (5) through mesylation (4) (SN2 reaction). Following the reduction of diazide,
using palladium as a catalyst gave the diamine (6).
In order to form the next imidazoline (7) ring, the corresponding aryl imidate was reacted
with diamino-N-Boc pyrrolidine; then, the Swern oxidation was accomplished to synthesize the
2,5-dihydropyrrolo imidazole core (8). Next, 4-chloro-2-methylthio-pyrimidine was introduced to
the core through SNAr reaction under microwave irradiation (9). The methyl sulfide was oxidized to
methyl sulfone (10) by potassium peroximonosulfate and substituted with the amide-coupled amine
group through another SNAr (11a–d, 12a–d, 13a–d, 14a, 14c and 15a). The final products (17a–d, 18a–d,
19a–d, 20a, 20c and 21a) were obtained after Boc deprotection by HCl and phenylcarbamate treatment.
Another final product (22a) was obtained using 4-nitrophenyl chloroformate.

Int. J. Mol. Sci. 2020, 21, 1698
3 of 17
Scheme 1. Synthesis of 1-pyrimidinyl-2-aryl-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide.
(rt: room temperature, *: Stereocenter).
After synthesis of all the compounds (17a–d, 18a–d, 19a–d, 20a, 20c and 21a), the JNK3 inhibitory
activity of each compound was evaluated (Table 1). Most of the synthesized compounds exhibited good

Int. J. Mol. Sci. 2020, 21, 1698
4 of 17
activity against JNK3. In particular, 18a showed the most potent activity against JNK3, with an IC50
value of 2.69 nM. Structure activity relationships (SARs) were inferred from potency data. First, when
comparing the activity by the aryl group substitution, the compounds with the relatively large groups
such as naphtyl and dichlorophenyl groups showed good inhibitory activity toward JNK3, rather than
those with dioxolphenyl and dihydrobenzofuranphenyl groups (a and b vs. c and d). We think that the
aryl group occupied a larger hydrophobic space under the roof and induced hydrophobic interaction.
This was assumed from the docking studies of the previous inhibitor of JNK3. Moreover, the napthyl
and dichlorophenyl rings have higher electron densities, so could form stronger interactions with
the surrounded residues, supporting better activities. Secondly, when the piperidin-4-ol (17a) was
substituted in the position of the carboxamide in 2, 5-dihydropyrrolo-1-carboxamide, the activity
falls to half that of the corresponding carboxamide (17a vs. 22a). Next, when the cyclopropyl group
in the solvent exposure part was replaced with a cyclobutyl or cyclopentyl group, the inhibitory
activity decreased approximately two- to three-fold (17a vs. 20a, 20c, and 21a). In an effort to reduce
the molecular weight, the piperidine ring was diversified into pyrrolidine with less carbon atoms
(n = 2). Surprisingly, when (R)-aminopyrrolidine was coupled to the pyrimidyl group instead of the
(S)-aminopiperidine, the activities were increased by approximately seven- to ten-fold (17 vs. 19)
.
Interestingly, when (R)-aminopyrrolidine was introduced, the activity was significantly increased by
approximately four- to five-fold (17 vs. 18). This also suggested that the size and configuration of the
amino group in the ring should be considered important for binding, even in the solvent exposure
part for optimal extra-hydrogen bonding. The extra hydrogen bonding seemed more plausible in
(R)-pyrrolidine (18) than in the cases of (S)-piperidine (17) and (S)-pyrrolidine (19).
A docking study was conducted to understand the binding mode of the novel JNK3 inhibitor 18a
(Figure 2). When we performed the docking experiment of 18a with a known JNK3 structure (3OY1),
it was shown that many of the interactions could contribute to complex stabilization. First, the amino
pyrimidine is a hinge binder and forms two hydrogen interactions with the Met149 of JNK3. The oxygen
of cyclopropyl carboxamide in compound 18a could form hydrogen bond interaction with Gln155 in
the extended hinge region. The two hydrogen bonds were monitored between the oxygen in the
carboxamide of 2,5-dihydropyrrole and the side chain of Asn152, and between the NH2 in the carboxamide
of 2,5-dihydropyrrole-1-carboxamide and the side chain of Ser72. Finally, the dichlorophenyl ring of
compound 18a fits into the hydrophobic pocket and forms a halogen bond with Ala93.
Figure 2. Docking structures of 18a at JNK3 (PDB: 3OY1) and 2D interaction map.

Int. J. Mol. Sci. 2020, 21, 1698
5 of 17
Table
1.
Enzymatic
activities
of
1-pyrimidinyl-2-aryl-4,
6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide derivatives.
No
Ar
m
n
* (R/S)
JNK3 IC50 (nM)
17a
18a
19a
20a
21a
22a
3
2
2
3
3
3
1
1
1
2
3
1
S
R
S
S
S
S
10.4
2.69
113
29.7
24.8
18.6
17b
18b
19b
3
2
2
1
1
1
S
R
S
4.81
4.52
48.2
17c
18c
19c
20c
3
2
2
3
1
1
1
2
S
R
S
131
37.3
744
225
S
17d
18d
19d
3
2
2
1
1
1
S
R
S
41.2
16.7
529
JNKI VIII [16,17]
5
*: Stereocenter
Next, we performed kinases panel screening in duplicate for compound 18a on 38 different protein
kinases at a single-dose concentration of 10 M (Table 2). The compound 18a was indeed a selective
JNK3 inhibitor with an excellent selectivity profile, only having slight activities on JNK2, GSK3
and RIPK3 more than 50%. When we further determine the IC50 of 18a on these three protein kinases
and compared with it on JNK3, the selectivity was still maintained. And since the GSK3 and RIPK3
µ
β,
β
are said to be associated with neurodegenerative disease caused by all neuronal apoptosis [18–23],
we could manipulate these characters of 18a for further developments.
Table 2. Percentages of enzymatic inhibition exerted by 10
µM of 18a on 38 selected protein kinases [24]
and enzymatic activities on selected protein kinases.
IC50 (M)
Selectivity/JNK3 of 18a
Kinase
18a
Control
2.69 × 10−9
5.53 × 10−6
2.25 × 10−7
>1.00 × 10−5
5.00 × 10−9 (JNKI VIII)
2.30 × 10−9 (Staurosporine)
1.92 × 10−6 (Staurosporine)
2.65 × 10−7 (GW5074)
JNK3
GSK3β
JNK2
-
>2000 fold
>80 fold
>100 fold
RIPK3

Int. J. Mol. Sci. 2020, 21, 1698
6 of 17
3. Materials and Methods
3.1. Chemistry
3.1.1. General Chemical Methods
All chemicals were of reagent grade and were purchased from Sigma-Aldrich, Inc. (Seoul, Korea).
Separation of the compounds by column chromatography was carried out with silica gel 60
(200–300 mesh ASTM, E. Merck, Darmstadt, Germany). The quantity of silica gel used was 50–100 times
the weight charged on the column. Thin layer chromatography (TLC) was run on silica gel-coated
aluminum sheets (silica gel 60 GF254, E. Merck, Darmstadt, Germany) and visualized under ultraviolet
(UV) light (254 nm). Both 1H Nuclear Magnetic Resonance (NMR )and 13C NMR spectra were recorded
on a Bruker model digital AVANCE III 400 MHz spectrometer (Billerica, MA, USA) at 25 ◦C using
tetramethylsilane (TMS) as an internal standard. High-resolution Mass Spectra (HR/MS) experiments
were conducted with a Finnigan LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific Inc.,
New York, NY, USA) operated in positive-ion electrospray mode.
3.1.2. General Syntheses of tert-Butyl 2, 5-Dihydro-1H-Pyrrole-1-Carboxylate (2)
Compound
1
(4.65 mmol) was dissolved in dimethyl formamide (5 mL), and then sodium hydride
was added to the mixture and stirred
(10.23 mmol) was added at 0 ◦C and stirred for 10 min. Compound
1
at room temperature for 15 min, followed by stirring at 65 ◦C for 4 to 6 h. It was then cooled to ambient
temperature, extracted with an organic layer (Ethylacetate:n-Hexane (EA:HEX) = 1:4), and washed with
water. This was followed by drying with anhydrous magnesium sulfate and evaporation of the solvent to
obtain compound
9H); HRMS m/z calcd for C9H15NO2 169.2240; found 170.0130 (M+H+).
3 δ 5.76 (s, 2H), 4.11 (s, 4H), 1.47 (s,
as a yellow oil. (45%); 1H NMR (400 MHz, CDCl3):
3.1.3. General Syntheses of Tert-Butyl (3R, 4S)-3, 4-Dihydroxypyrrolidine-1-Carboxylate (3)
Compound (6.3 mmol) was dissolved in tetrahydrofuran (15.8 mL) and we then slowly dropped
2
the mixture of osmium tetroxide (0.113 mmol) and N-methylmorpholine-N-oxide (8.29 mmol) in
15.8 mL of water. The mixture was stirred at room temperature for 3 to 5 h. It was then concentrated
in vacuo, extracted with ethyl acetate, and washed with water. This was followed by drying with
anhydrous magnesium sulfate, evaporation of the solvent, and then purification of the product by
column chromatography on silica gel using a mobile phase of EA: HEX (3: 1) to obtain compound
3
as a yellow oil. (59%); 1H NMR (400 MHz, CDCl3):
δ
4.25 (qd, J = 4.4, 2.1 Hz, 2H), 3.59 (dd, J = 11.4,
5.7 Hz, 2H), 3.34 (dd, J = 11.3, 3.8 Hz, 2H), 1.45 (s, 9H); HRMS m/z calcd for C9H17NO4 203.2380;
found 204.4411 (M+H+).
3.1.4. General Syntheses of Tert-Butyl (3R, 4S)-3, 4-Bis((Methylsulfonyl)Oxy)Pyrrolidine-1-Carboxylate (4)
Compound 3 (0.96 mmol) was dissolved in dichloromethane (4.8 mL), and then methanesulfonyl
chloride (2.11 mmol) and triethylamine (2.11 mmol) were added and stirred at room temperature for
30 min to 1 h. The reaction mixture was washed with water and brine. This was followed by drying
with anhydrous magnesium sulfate and evaporation of the solvent to obtain compound
4 as a white solid.
(90%); 1H NMR (400 MHz, CDCl3):
δ
5.17 (t, J = 4.0 Hz, 2H), 3.84–3.74 (m, 2H), 3.68–3.59 (m, 2H), 3.14 (d,
J = 5.6 Hz, 6H), 1.46 (s, 9H); HRMS m/z calcd for C11H21NO8S2 359.4080; found 360.0501 (M+H+).
3.1.5. General Syntheses of Tert-Butyl (3S, 4R)-3,4-Diazidopyrrolidine-1-Carboxylate (5)
Compound 4 (3.3 mmol) was dissolved in dimethylformamide (33 mL), and then sodium azide
(33 mmol) was added and the mixture was stirred at 90 ◦C for 24 h. The mixture was then cooled
to ambient temperature, extracted with ethyl acetate, and washed with brine. After drying with
anhydrous magnesium sulfate and concentration of the solvent in vacuo, the product was purified by
column chromatography on silica gel using a mobile phase of EA:HEX (1:4) to obtain compound
5

Int. J. Mol. Sci. 2020, 21, 1698
7 of 17
as a yellow oil. (79%); 1H NMR (400 MHz, CDCl3):
δ
4.08 (d, J = 3.3 Hz, 2H), 3.63 (dd, J = 8.8, 5.5 Hz,
2H), 3.44 (ddd, J = 16.3, 10.8, 4.1 Hz, 2H), 1.46 (s, 9H); HRMS m/z calcd for C9H15N7O2 253.2660;
found 254.3558 (M+H+).
3.1.6. General Synthesis of Tert-Butyl (3S, 4R)-3,4-Diaminopyrrolidine-1-Carboxylate (6)
Compound
on carbon (0.52 mmol) was added. It was stirred for 4 h at room temperature under hydrogen gas.
The mixture was filtered through a celitepad, and the filtrate was concentrated to obtain compound
as a yellow oil. (98%); 1H NMR (400 MHz, DMSO-d6):
3.26 (dd, J = 10.9, 5.9 Hz, 3H), 3.14 (dq, J = 9.6,
5 (2.6 mmol) was dissolved in methanol (10.4 mL), and then palladium hydroxide
6
δ
4.8 Hz, 2H), 2.95 (dd, J = 10.6, 4.9 Hz, 2H), 1.38 (s, 9H). HRMS m/z calcd for C9H19N3O2 201.2700;
found 202.3284 (M+H+).
3.1.7. General Syntheses of Compounds 7a-d
Tert-Butyl (3aS,6aR)-2-(3,4-Dichlorophenyl)-3a,4,6,6a-Tetrahydropyrrolo-Imidazole-5(1H) -Carboxylate (7a)
Compound
6 (2.69 mmol) and aryl-substituted imidate (2.5 mmol) were dissolved in ethanol
(13.4 mL) and stirred at 80 ◦C for 1 to 2 h. The mixture was cooled to ambient temperature and then
concentrated in vacuo. The concentrated mixture was extracted with ethyl acetate and washed with
brine. This was followed by drying with anhydrous magnesium sulfate, and the solvent was purified
by column chromatography on silica gel using a mobile phase of EA:HEX (3:1) to obtain compound 7a
as a white solid. (47%); 1H NMR (400 MHz, MeOD):
δ 7.96 (d, J = 2.0 Hz, 1H), 7.71 (dd, J = 8.4, 2.0 Hz,
1H), 7.63 (d, J = 8.4 Hz, 1H), 4.65 (s, 2H), 3.71 (d, J = 12.0 Hz, 2H), 3.55–3.44 (m, 2H), 1.43 (s, 9H); HRMS
m/z calcd for C16H19Cl2N3O2 356.2470; found 357.4684 (M+H+).
Tert-Butyl
(3aS,6aR)-2-(Naphthalen-2-yl)-3a,4,6,6a-Tetrahydropyrrolo[3,4-d]Imidazole-5(1H)-
Carboxylate (7b)
Compound 7b was obtained as a white solid by the same procedure as above. (crude yield: 95%);
1H NMR (400 MHz, DMSO-d6):
8.77 (d, J = 1.4 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 8.10–8.03 (m, 3H),
δ
7.74 (ddd, J = 14.4, 7.9, 1.2 Hz, 2H), 4.94 (d, J = 1.4 Hz, 2H), 3.82 (d, J = 12.5 Hz, 2H), 3.45 (d, J = 12.4 Hz,
2H), 3.32 (s, 1H), 1.32 (s, 9H); HRMS m/z calcd for C20H23N3O2 337.4230; found 338.3165 (M+H+).
Tert-Butyl (3aS,6aR)-2-(Benzo[d][1,3]Dioxol-5-yl)-3a,4,6,6a-Tetrahydro Pyrrolo[3,4-d]Imidazole
-5(1H)-Carboxylate (7c)
Compound 7c was obtained as a white solid by the same procedure as above. (crude yield: 98%);
1H NMR (400 MHz, DMSO-d6):
δ 7.68 (d, J = 11.4 Hz, 2H), 7.21 (d, J = 8.1 Hz, 1H), 6.21 (s, 2H), 4.85 (s,
2H), 3.76 (d, J = 12.5 Hz, 2H), 3.39 (d, J = 12.1 Hz, 2H), 3.32 (s, 1H), 1.34 (s, 9H); HRMS m/z calcd for
C17H21N3O4 331.3720; found 332.3018 (M+H+).
Tert-Butyl (3aS,6aR)-2-(2,3-Dihydrobenzofuran-5-yl)-3a,4,6,6a-Tetrahyd Ropyrrolo[3,4-d]Imidazole
-5(1H)-Carboxylate (7d)
Compound 7d was obtained as a white solid by the same procedure as above. (crude yield: 98%);
1H NMR (400 MHz, CDCl3):
δ 8.15 (s, 1H), 8.08 (d, J = 8.5 Hz, 1H), 6.74 (d, J = 8.5 Hz, 1H), 4.85 (s, 2H),
4.62 (t, J = 8.8 Hz, 2H), 4.01 (d, J = 12.5 Hz, 2H), 3.44 (d, J = 12.1 Hz, 2H), 3.18 (t, J = 8.7 Hz, 2H), 1.39 (s,
9H); HRMS m/z calcd for C18H23N3O3 329.4000; found 330.3653 (M+H+).
3.1.8. General Syntheses of Compounds 8a-d
Tert-Butyl 2-(3,4-Dichlorophenyl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5 (1H)-Carboxylate (8a)
Oxalyl chloride (0.59 mmol) and dimethyl sulfoxide (1.18 mmol) were dissolved in 7 mL of
dichloromethane, stirred at
dissolved in 5 mL of dichloromethane at
−
78 ◦C for 10 min, and then slowly added to compound 7a (0.59 mmol)
−
78 ◦C for 30 min. Then, triethylamine (5.9 mmol) was added

Int. J. Mol. Sci. 2020, 21, 1698
8 of 17
slowly and stirred at room temperature for 1 h 30 min. The reaction mixture was washed with water
and brine, followed by drying with anhydrous magnesium sulfate and concentration of the solvent
in vacuo to obtain compound 8a as a white solid. (50%); 1H NMR (400 MHz, Dimethyl sulfoxide-d6
(DMSO-d6):
δ 12.82 (d, J = 24.4 Hz, 1H), 8.41 (s, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.99–7.88 (m, 3H), 7.59–7.48
(m, 2H), 4.50 (s, 2H), 4.33 (d, J = 10.1 Hz, 2H), 1.47 (s, 9H); HRMS m/z calcd for C16H17Cl2N3O2
354.2310; found 355.4510 (M+H+).
Tert-Butyl 2-(Naphthalen-2-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (8b)
Compound 8b was obtained as a white solid by the same procedure as above. (51%); 1H NMR
(400 MHz, DMSO):
δ 12.82 (d, J = 24.4 Hz, 1H), 8.41 (s, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.99–7.88 (m, 3H),
7.59–7.48 (m, 2H), 4.50 (s, 2H), 4.33 (d, J = 10.1 Hz, 2H), 1.47 (s, 9H); HRMS m/z calcd for C20H21N3O2
335.4070; found 336.2996 (M+H+).
Tert-Butyl 2-(Benzo[d][1,3]Dioxol-5-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (8c)
Compound 8c was obtained as a white solid by the same procedure as above. (50%); 1H NMR
(400 MHz, CDCl3):
δ 7.32 (dd, J = 10.6, 1.6 Hz, 2H), 6.81 (d, J = 8.0 Hz, 1H), 5.99 (s, 2H), 4.49–4.39 (m,
4H), 1.51 (s, 9H); HRMS m/z calcd for C17H19N3O4 329.3560; found 330.3209 (M+H+).
Tert-Butyl 2-(2,3-Dihydrobenzofuran-5-yl)-4,6- Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (8d)
Compound 8d was obtained as a white solid by the same procedure as above. (50%); 1H NMR
(400 MHz, CDCl3):
δ 7.75 (s, 1H), 7.55 (dd, J = 8.3, 1.9 Hz, 1H), 6.78 (d, J = 8.3 Hz, 1H), 4.61 (t, J = 8.8 Hz,
2H), 4.50–4.41 (m, 4H), 3.22 (t, J = 8.7 Hz, 2H), 1.51 (s, 9H); HRMS m/z calcd for C18H21N3O3 327.3840;
found 328.3040 (M+H+).
3.1.9. General Syntheses of Compounds 9a–d
Tert-Butyl 2-(3,4-Dichlorophenyl)-1-(2-(Methylthio)Pyrimidin-4-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole
-5(1H)-Carboxylate (9a)
Compound 8a (0.75 mol), 4-chloro-2-(methylthio)pyrimidine (0.75 mmol) and cesium carbonate
(0.9 mmol) were dissolved in 7.5 mL of N, N-dimethylformamide and stirred for 2 h at 100 ◦C in a
microwave reactor. After 2 h, the reaction mixture was extracted with ethyl acetate and washed with
water and brine. After drying over anhydrous magnesium sulfate and concentration, the product
was purified by column chromatography on silica gel using a mobile phase of EA:HEX (1:2) to obtain
compound 9a as a yellow solid. (50%); 1H NMR (400 MHz, CDCl3)
δ 8.28 (dd, J = 7.6, 5.5 Hz, 1H), 8.13
(d, J = 16.5 Hz, 1H), 7.88 (t, J = 8.7 Hz, 3H), 7.62–7.53 (m, 3H), 6.42 (d, J = 5.5 Hz, 1H), 4.86–4.79 (m, 2H),
4.59 (s, 2H), 2.55 (d, J = 3.4 Hz, 3H), 1.54 (s, 9H).; HRMS m/z calcd for C21H21Cl2N5O2S 477.3920,
Found 478.4457 (M+H+).
Tert-Butyl
1-(2-(Methylthio)Pyrimidin-4-yl)-2-(Naphthalen-2-yl)-4,6-Dihydropyrrolo
[3,4-d]Imidazole-5(1H)-Carboxylate (9b)
Compound 9b was obtained as a yellow solid by the same procedure as above. (22%); 1H NMR
(400 MHz, CDCl3):
δ 8.28 (dd, J = 7.6, 5.5 Hz, 1H), 8.13 (d, J = 16.5 Hz, 1H), 7.89 (d, J = 9.0 Hz, 3H),
7.62–7.53 (m, 2H), 7.53–7.47 (m, 1H), 6.42 (d, J = 5.5 Hz, 1H), 4.86–4.79 (m, 2H), 4.59 (s, 2H), 2.55 (d,
J = 3.4 Hz, 3H), 1.54 (s, 9H); HRMS m/z calcd for C25H25N5O2S 459.5680; found 460.4038 (M+H).
Tert-Butyl
2-(Benzo[d][1,3]Dioxol-5-yl)-1-(2-(Methylthio)Pyrimidin-4-yl)-4,6-Dihydropyrrolo[3,4-d]
Imidazole-5(1H)-Carboxylate (9c)
Compound 9c was obtained as a yellow solid by the same procedure as above. (47%); 1H NMR
(400 MHz, CDCl3):
δ 8.35 (dd, J = 5.5, 1.1 Hz, 1H), 7.00–6.93 (m, 2H), 6.85 (d, J = 7.9 Hz, 1H), 6.46
(t, J = 5.6 Hz, 1H), 6.04 (s, 2H), 4.83–4.72 (m, 2H), 4.54–4.45 (m, 2H), 2.56 (d, J = 2.1 Hz, 3H), 1.52 (d,
J = 1.8 Hz, 9H); HRMS m/z calcd for C22H23N5O4S 453.5170; found 454.3178 (M+H+).

Int. J. Mol. Sci. 2020, 21, 1698
9 of 17
Tert-Butyl 2-(2,3-Dihydrobenzofuran-5-yl)-1-(2- (Methylthio)Pyrimidin-4-yl)-4,6-Dihydropyrrolo[3,4-d]
Imidazole-5(1H)-Carboxylate (9d)
Compound 9d was obtained as a yellow solid by the same procedure as above. (52%); 1H NMR
(400 MHz, CDCl3):
δ 8.32 (d, J = 5.5 Hz, 1H), 7.38 (s, 1H), 7.19 (d, J = 8.3 Hz, 1H), 6.80 (d, J = 8.3 Hz,
1H), 6.46 (t, J = 5.5 Hz, 1H), 4.82–4.74 (m, 2H), 4.65 (t, J = 8.8 Hz, 2H), 4.51 (dd, J = 12.7, 9.5 Hz, 2H), 3.24
(t, J = 8.8 Hz, 2H), 2.57 (d, J = 1.3 Hz, 3H), 1.53 (d, J = 1.7 Hz, 9H); HRMS m/z calcd for C23H25N5O3S
454.5450; found 452.6696 (M+H+).
3.1.10. General Syntheses of Compounds 11a–d
Tert-Butyl
(S)-1-(2-((1-(Cyclopropanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin
-4-yl)-2-(3,4-Dichlorophenyl)-4,6- Dihydropyrrolo[3,4-d]Imidazole -5(1H)-Carboxylate (11a)
Compound 9a (0.16 mmol) was dissolved in 2 mL of methanol, and then potassium
peroxomonosulfate (0.8 mmol) dissolved in 2 mL of water was added, followed by stirring
at ambient temperature for 2 h.
Methanol was concentrated and extracted with ethyl
acetate and washed with water and brine, followed by drying with anhydrous magnesium
sulfate and concentration of the solvent in vacuo to obtain compound 10a as a white solid.
Next, (S)-(3-aminopiperidin-1-yl)(cyclopropyl)methanone (0.32 mmol) was dissolved in 1 mL of
dimethylformamide, and 44.5
µ
L (0.32 mmol) of triethylamine were added. Then,◦compound
10a (0.14 mmol) dissolved in 3 mL of tetrahydrofuran was added and stirred at 80 C for 24 h.
Tetrahydrofuran was concentrated in vacuo, extracted with ethyl acetate, and washed with water and
brine. After drying over anhydrous magnesium sulfate and concentration, the product was purified by
column chromatography on silica gel using a mobile phase of EA:HEX (5:1) to obtain compound 11a
as a yellow solid. (48%); 1H NMR (400 MHz, CDCl3):
δ 8.20 (s, 1H), 7.66 (s, 1H), 7.47 (d, J = 8.3 Hz,
1H), 7.35–7.27 (m, 1H), 6.13 (d, J = 5.4 Hz, 1H), 4.71 (d, J = 33.9 Hz, 2H), 4.49 (d, J = 25.9 Hz, 2H), 3.75
(d, J = 31.6 Hz, 5H), 1.79–1.59 (m, 5H), 1.52 (d, J = 2.8 Hz, 9H), 1.01 (s, 2H), 0.77 (s, 2H); HRMS m/z
calcd for C29H33Cl2N7O3 598.5290; found 599.5036 (M+H+).
Tert-Butyl
(S)-1-(2-((1-(Cyclopropanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin-4-yl)-2-(Naphthalen
-2-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (11b)
Compound 11b was obtained as a yellow solid by the same procedure as above. (38%); 1H NMR
(400 MHz, MeOD):
δ 8.34–8.26 (m, 1H), 7.76–7.70 (m, 1H), 7.62 (dd, J = 8.3, 1.1 Hz, 1H), 7.41 (ddd,
J = 8.2, 4.0, 2.0 Hz, 1H), 6.31 (d, J = 5.2 Hz, 1H), 4.77 (d, J = 12.9 Hz, 2H), 4.48 (d, J = 2.6 Hz, 2H),
3.96–3.54 (m, 4H), 2.32–2.03 (m, 4H), 1.56 (d, J = 2.5 Hz, 9H), 0.94–0.85 (m, 4H); HRMS m/z calcd for
C33H37N7O3 579.2958; found 580.5351 (M+H).
Tert-Butyl
(S)-2-(Benzo[d][1,3]Dioxol-5-yl)-1-(2-((1-(Cyclopropanecarbonyl)Piperidin-3-yl)Amino)
Pyrimidin -4-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (11c)
Compound 11c was obtained as a yellow solid by the same procedure as above. (52%); 1H NMR
(400 MHz, CDCl3):
δ 8.11 (s, 1H), 6.98–6.88 (m, 2H), 6.81 (d, J = 8.0 Hz, 1H), 6.02 (d, J = 8.7 Hz, 3H), 4.69
(d, J = 27.0 Hz, 2H), 4.46 (d, J = 26.1 Hz, 2H), 3.97–3.52 (m, 5H), 1.82–1.56 (m, 5H), 1.50 (d, J = 2.4 Hz,
9H), 1.02–0.92 (m, 2H), 0.76 (d, J = 3.2 Hz, 2H); HRMS m/z calcd for C30H35N7O5 573.6540; found
574.4855 (M+H).
Tert-Butyl
(S)-1-(2-((1-(Cyclopropanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin-4-yl)-2-(2,3-
Dihydrobenzofuran-5-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (11d)
Compound 11d was obtained as a yellow solid by the same procedure as above. (52%); 1H NMR
(400 MHz, CDCl3):
δ 8.09 (s, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.17 (s, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.07 (s,
1H), 4.71 (d, J = 29.1 Hz, 2H), 4.62 (t, J = 8.8 Hz, 2H), 4.47 (d, J = 26.7 Hz, 2H), 3.70 (dd, J = 91.3, 72.0 Hz,
6H), 3.22 (t, J = 8.7 Hz, 2H), 1.80–1.56 (m, 5H), 1.51 (d, J = 2.5 Hz, 9H), 1.00 (s, 2H), 0.88 (d, J = 6.5 Hz,
2H); HRMS m/z calcd for C31H37N7O4 571.6820; found 572.2907 (M+H).

Int. J. Mol. Sci. 2020, 21, 1698
10 of 17
3.1.11. General Syntheses of Compounds 12a–d
Tert-Butyl
(R)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(3,4-
Dichlorophenyl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (12a)
Compound 9a (0.16 mmol) was dissolved in 2 mL of methanol, and then potassium
peroxomonosulfate (0.8 mmol) dissolved in 2 mL of water was added, followed by stirring
at ambient temperature for 2 h. Methanol was concentrated and extracted with ethyl acetate
and washed with water and brine. This was followed by drying with anhydrous magnesium
sulfate and concentration of the solvent in vacuo to obtain compound 10a as white solid.
Next, (R)-(3-aminopirrolidine-1-yl)(cyclopropyl)methanone (0.32 mmol) was dissolved in 1 mL
of dimethylformamide, and 44.5
µ
l (0.32 mmol) of triethylamine were added. Then,◦compound
10a (0.14 mmol) dissolved in 3 mL of tetrahydrofuran was added and stirred at 80 C for 24 h.
Tetrahydrofuran was concentrated in vacuo, extracted with ethyl acetate, and washed with water and
brine. After drying over anhydrous magnesium sulfate and concentration, the product was purified by
column chromatography on silica gel using a mobile phase of EA: HEX (5: 1) to obtain compound 12a
as a yellow solid. (38%); 1H NMR (400 MHz, MeOD):
δ 8.34–8.26 (m, 1H), 7.76–7.70 (m, 1H), 7.62 (dd,
J = 8.3, 1.1 Hz, 1H), 7.41 (ddd, J = 8.2, 4.0, 2.0 Hz, 1H), 6.31 (d, J = 5.2 Hz, 1H), 4.77 (d, J = 12.9 Hz, 2H),
4.48 (d, J = 2.6 Hz, 2H), 3.96–3.54 (m, 4H), 2.32–2.03 (m, 4H), 1.56 (d, J = 2.5 Hz, 9H), 0.94–0.85 (m, 4H);
HRMS m/z calcd for C28H31Cl2N7O3 584.5020; found 585.3686 (M+H).
Tert-Butyl (R)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(Naphthalen-2
-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (12b)
Compound 12b was obtained as a yellow solid by the same procedure as above. (30%); 1H NMR
(400 MHz, CDCl3):
δ 8.14–8.00 (m, 2H), 7.85 (d, J = 7.9 Hz, 3H), 7.58–7.49 (m, 3H), 6.16–6.03 (m, 1H),
4.77 (d, J = 16.4 Hz, 2H), 4.53 (d, J = 26.8 Hz, 2H), 3.79–3.50 (m, 4H), 2.18 (d, J = 13.6 Hz, 4H), 1.53 (s,
9H), 1.00 (s, 2H), 0.78 (d, J = 5.1 Hz, 2H); HRMS m/z calcd for C32H35N7O3 565.6780; found 566.2753
(M+H).
Tert-Butyl
(R)-2-(Benzo[d][1,3]Dioxol-5-yl)-1-(2-((1-(Cyclopropanecarbonyl)
Pyrrolidine-3-yl)
Amino)Pyrimidin-4-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (12c)
Compound 12c was obtained as a yellow solid by the same procedure as above. (44%); 1H NMR
(400 MHz, CDCl3): 8.11 (dd, J = 11.3, 5.3 Hz, 1H), 6.98–6.92 (m, 2H), 6.81 (dd, J = 8.0, 5.6 Hz, 1H),
δ
6.06–6.00 (m, 3H), 4.71 (dd, J = 23.3, 9.4 Hz, 2H), 4.43 (s, 2H), 3.80–3.58 (m, 4H), 2.37–1.95 (m, 4H),
1.52–1.48 (m, 9H), 0.98 (d, J = 4.8 Hz, 2H), 0.78–0.74 (m, 2H); HRMS m/z calcd for C29H33N7O5
559.6270; found 560.4778 (M+H).
Tert-Butyl
(R)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)
-2-(2,3-
Dihydrobenzofuran-5-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (12d)
Compound 12d was obtained as a yellow solid by the same procedure as above. (48%); 1H NMR
(400 MHz, CDCl3): 8.09 (dd, J = 12.1, 5.2 Hz, 1H), 7.35 (d, J = 10.3 Hz, 1H), 7.21–7.14 (m, 1H), 6.77
δ
(dd, J = 8.2, 3.7 Hz, 1H), 6.10 (ddd, J = 15.8, 12.2, 5.4 Hz, 1H), 4.82–4.68 (m, 2H), 4.63 (d, J = 8.8 Hz, 2H),
4.43 (s, 2H), 3.99–3.53 (m, 5H), 3.22 (t, J = 8.7 Hz, 2H), 2.39–2.05 (m, 2H), 1.92 (dd, J = 12.5, 6.2 Hz, 1H),
1.53–1.48 (m, 9H), 0.77 (dd, J = 7.8, 4.7 Hz, 4H); HRMS m/z calcd for C30H35N7O4 557.6550; found
558.2751 (M+H).
3.1.12. General Syntheses of Compounds 13a–d
Tert-Butyl
(S)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(3,4-
Dichlorophenyl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (13a)
Compound9a(0.16mmol)wasdissolvedin2mLofmethanol, andthenpotassiumperoxomonosulfate
(0.8 mmol) dissolved in 2 mL of water was added, followed by stirring at ambient temperature for

Int. J. Mol. Sci. 2020, 21, 1698
11 of 17
2 h. Methanol was concentrated and extracted with ethyl acetate and washed with water and brine,
followed by drying with anhydrous magnesium sulfate and concentration of the solvent in vacuo to
obtain compound 10a as white solid. (S)-(3-aminopirrolidine-1-yl)(cyclopropyl)methanone (0.32 mmol)
was dissolved in 1 mL of dimethylformamide, and 44.5 µL (0.32 mmol) of triethylamine were added.
Then, compound 10a (0.14 mmol) dissolved in 3 mL of tetrahydrofuran was added and stirred at 80 ◦C
for 24 h. Tetrahydrofuran was concentrated in vacuo, extracted with ethyl acetate, and washed with water
and brine. After drying over anhydrous magnesium sulfate and concentration, the product was purified
by column chromatography on silica gel using a mobile phase of EA: HEX (5: 1) to obtain compound 13a
as a yellow solid. (32%); 1H NMR (400 MHz, MeOD):
δ 8.34–8.26 (m, 1H), 7.76–7.70 (m, 1H), 7.62 (dd,
J = 8.3, 1.1 Hz, 1H), 7.41 (ddd, J = 8.2, 4.0, 2.0 Hz, 1H), 6.31 (d, J = 5.2 Hz, 1H), 4.77 (d, J = 12.9 Hz, 2H),
4.48 (d, J = 2.6 Hz, 2H), 3.89–3.48 (m, 4H), 2.25–2.02 (m, 4H), 1.56 (d, J = 2.5 Hz, 9H), 0.96–0.84 (m, 4H);
HRMS m/z calcd for C28H31Cl2N7O3 584.5020; found 585.3209 (M+H).
Tert-Butyl (S)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(Naphthalen
-2-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (13b)
Compound 13b was obtained as a yellow solid by the same procedure as above. (30%); 1H NMR
(400 MHz, CDCl3):
δ 8.10–8.02 (m, 2H), 7.85 (d, J = 7.2 Hz, 3H), 7.56–7.48 (m, 3H), 6.18–6.02 (m, 1H), 4.77
(d, J = 16.3 Hz, 2H), 4.53 (d, J = 27.3 Hz, 2H), 3.76–3.55 (m, 4H), 2.28–2.03 (m, 4H), 1.53 (s, 9H), 1.00–0.95
(m, 2H), 0.77 (d, J = 4.3 Hz, 2H); HRMS m/z calcd for C32H35N7O3 565.6780; found 566.5274 (M+H).
Tert-Butyl
(S)-2-(Benzo[d][1,3]Dioxol-5-yl)-1-(2-((1-(Cyclopropanecarbonyl)
Pyrrolidine-
3-yl)Amino)Pyrimidin-4-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (13c)
Compound 13c was obtained as a yellow solid by the same procedure as above. (26%); 1H NMR
(400 MHz, CDCl3): 8.18–8.09 (m, 1H), 6.97 (ddd, J = 8.7, 5.3, 1.5 Hz, 2H), 6.83 (d, J = 8.0 Hz, 1H),
δ
6.19–6.06 (m, 1H), 6.02 (d, J = 1.1 Hz, 2H), 4.83–4.64 (m, 2H), 4.57–4.42 (m, 2H), 4.03–3.52 (m, 5H),
2.44–2.07 (m, 2H), 1.99–1.81 (m, 1H), 1.52–1.43 (m, 9H), 1.01 (d, J = 2.4 Hz, 2H), 0.78 (dd, J = 7.5, 4.3 Hz,
2H); HRMS m/z calcd for C29H33N7O5 559.6270; found 560.2543 (M+H).
Tert-Butyl
(S)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(2,3-
Dihydrobenzofuran-5-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (13d)
Compound 13d was obtained as a yellow solid by the same procedure as above. (52%); 1H NMR
(400 MHz, CDCl3)
δ 8.14–8.03 (m, 1H), 7.35 (d, J = 11.0 Hz, 1H), 7.18 (d, J = 7.2 Hz, 1H), 6.78 (dd,
J = 8.2, 3.9 Hz, 1H), 6.10 (ddd, J = 15.7, 12.5, 5.5 Hz, 1H), 4.75 (d, J = 1.9 Hz, 2H), 4.62 (d, J = 8.8 Hz, 2H),
4.44 (s, 2H), 3.85–3.53 (m, 5H), 3.21 (d, J = 8.7 Hz, 2H), 2.37–2.07 (m, 2H), 1.93 (dd, J = 12.4, 6.0 Hz,
1H), 1.54–1.49 (m, 9H), 1.00 (d, J = 2.3 Hz, 2H), 0.79–0.74 (m, 2H); HRMS m/z calcd for C30H35N7O4
557.6550; found 558.1865 (M+H).
3.1.13. General Syntheses of Compounds 14a and 14c
Tert-Butyl (S)-1-(2-((1-(Cyclobutanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin-4-yl)-2-(3,4 -Dichlorophenyl)
-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (14a)
Compound 9a (0.16 mmol) was dissolved in 2 mL of methanol, and then potassium
peroxomonosulfate (0.8 mmol) dissolved in 2 mL of water was added, followed by stirring at ambient
temperature for 2 h. Methanol was concentrated and extracted with ethyl acetate and washed with water
and brine, followed by drying with anhydrous magnesium sulfate and concentration of the solvent
in vacuo to obtain compound 10a as white solid. (S)-(3-aminopiperidin-1-yl)(cyclobutyl)methanone
(0.32 mmol) was dissolved in 1 mL of dimethylformamide, and 44.5 µl (0.32 mmol) of triethylamine
were added. Then, compound 10a (0.14 mmol) dissolved in 3 mL of tetrahydrofuran was added and
stirred at 80 ◦C for 24 h. Tetrahydrofuran was concentrated in vacuo, extracted with ethyl acetate,
and washed with water and brine. After drying over anhydrous magnesium sulfate and concentration,
the product was purified by column chromatography on silica gel using a mobile phase of EA: HEX (5:

Int. J. Mol. Sci. 2020, 21, 1698
12 of 17
1) to obtain compound 14a as a yellow solid. (49%); 1H NMR (400 MHz, CDCl3): δ 8.25–8.05 (m, 1H),
7.71–7.62 (m, 1H), 7.47 (dd, J = 10.5, 4.8 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 6.16 (d, J = 5.0 Hz, 1H), 4.70
(dd, J = 31.8, 22.8 Hz, 2H), 4.46 (t, J = 17.4 Hz, 2H), 3.97–3.54 (m, 3H), 3.42–3.13 (m, 3H), 2.39–2.09 (m,
4H), 2.00–1.62 (m, 6H), 1.50 (d, J = 2.4 Hz, 9H); HRMS m/z calcd for C30H35Cl2N7O3 612.5560; found
613.3670 (M+H).
Tert-Butyl (S)-2-(Benzo[d][1,3]Dioxol-5-yl)-1-(2-((1-(Cyclobutanecarbonyl)Piperidin-3-yl)Amino) Pyrimidin
-4-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (14c)
Compound 14c was obtained as a yellow solid by the same procedure as above. (20%); 1H NMR
(400 MHz, MeOD):
δ 8.28–8.14 (m, 1H), 7.03–6.83 (m, 3H), 6.28 (s, 1H), 6.04 (d, J = 2.2 Hz, 2H), 4.80 (s,
2H), 4.47 (d, J = 12.3 Hz, 2H), 4.06 (d, J = 81.6 Hz, 2H), 3.12–3.02 (m, 1H), 2.94 (s, 1H), 2.15–1.43 (m,
12H); HRMS m/z calcd for C31H37N7O5 587.6810; found 588.5726 (M+H).
3.1.14. General Syntheses of Tert-Butyl (S)-1-(2-((1-(Cyclopentanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin
-4-yl)-2-(3,4-Dichlorophenyl)-4,6- Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxylate (15a)
Compound 9a (0.16 mmol) was dissolved in 2 mL of methanol, and then potassium
peroxomonosulfate (0.8 mmol) dissolved in 2 mL of water was added, followed by stirring at ambient
temperature for 2 h. Methanol was concentrated and extracted with ethyl acetate and washed with water
and brine, followed by drying with anhydrous magnesium sulfate and concentration of the solvent in
vacuo to obtain compound 10a as white solid. (S)-(3-aminopiperidin-1-yl)(cyclopentyl)methanone
(0.32 mmol) was dissolved in 1 mL of dimethylformamide, and 44.5 µl (0.32 mmol) of triethylamine
were added. ◦Then, compound 10a (0.14 mmol) dissolved in 3 mL of tetrahydrofuran was added and
stirred at 80 C for 24 h. Tetrahydrofuran was concentrated in vacuo, extracted with ethyl acetate,
and washed with water and brine. After drying over anhydrous magnesium sulfate and concentration,
the product was purified by column chromatography on silica gel using a mobile phase of EA: HEX (5:
1) to obtain compound 15a as a yellow solid. (8%); 1H NMR (400 MHz, CDCl3):
δ 8.19 (t, J = 30.4 Hz,
1H), 7.68 (s, 1H), 7.51 (dd, J = 13.1, 6.2 Hz, 1H), 7.35–7.28 (m, 1H), 6.22 (s, 1H), 4.85–4.66 (m, 2H), 4.49
(d, J = 20.4 Hz, 2H), 3.80–3.50 (m, 4H), 2.92 (s, 2H), 1.75 (d, J = 38.6 Hz, 12H), 1.51 (d, J = 2.5 Hz, 9H);
HRMS m/z calcd for C31H37Cl2N7O3 626.5830; found 627.3383 (M+H).
3.1.15. General Syntheses of Compounds 17a–d, 18a–d, 19a–d, 20a, 20c, and 21a
(S)-1-(2-((1-(Cyclopropanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin-4-yl)-2-(3,4-Dichlorophenyl)
-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (17a)
Compound 11a (0.05 mol) was dissolved in 0.5 mL of 1,4-dioxane, and 0.25 mL of 4 M HCl
in 1,4-dioxane was added. The mixture was stirred at ambient temperature for 1 h 30 min. After
concentrating 1,4-dioxane in vacuo, compound 16 was obtained. Compound 16 (0.048 mol) was
dissolved in 0.48 mL of 1,4-dioxane, and then phenyl carbamate (0.048 mmol) and triethylamine
(0.048 mmol) were added, and the mixture was stirred at ambient temperature for 24 h. 1,4-Dioxane
was concentrated in vacuo, extracted with ethyl acetate, and washed with water and brine. After
drying with anhydrous magnesium sulfate and concentration of the solvent in vacuo, the product was
purified by column chromatography on silica gel using a mobile phase of MC:MeOH (10:1) to obtain
compound 17a as a white solid. (31%); 1H NMR (400 MHz, MeOD):
δ 8.36–8.23 (m, 1H), 7.69 (s, 1H),
7.59 (d, J = 8.2 Hz, 1H), 7.37 (t, J = 6.3 Hz, 1H), 6.33 (d, J = 75.5 Hz, 1H), 4.76 (s, 2H), 4.49 (dd, J = 11.6,
8.5 Hz, 2H), 4.06 (d, J = 60.6 Hz, 2H), 3.40–3.05 (m, 5H), 2.10–1.40 (m, 5H), 0.96–0.53 (m, 4H); HRMS
m/z calcd for C25H26Cl2N8O2 541.4370; found 542.4286 (M+H).
(S)-1-(2-((1-(Cyclopropanecarbonyl)piperidin-3-yl)Amino)Pyrimidin-4-yl)-2-(Naphthalen-2-yl)-4,6-
Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (17b)
Compound 17b was obtained as a white solid by the same procedure as above. (31%); 1H NMR
(400 MHz, MeOD): δ 8.29–8.05 (m, 2H), 7.92 (s, 3H), 7.65–7.39 (m, 3H), 6.26 (d, J = 102.0 Hz, 1H), 4.69

Int. J. Mol. Sci. 2020, 21, 1698
13 of 17
(d, J = 17.1 Hz, 2H), 4.63–4.48 (m, 2H), 4.19–3.72 (m, 2H), 3.29–2.31 (m, 3H), 2.17–1.43 (m, 5H), 0.90 (dt,
J = 73.7, 30.3 Hz, 4H); HRMS m/z calcd for C29H30N8O2 522.6130; found 523.4595 (M+H).
(S)-2-(Benzo[d][1,3]Dioxol-5-yl)-1-(2-((1-(Cyclopropanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin-4-yl)
-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (17c)
Compound 17c was obtained as a white solid by the same procedure as above. (47%); 1H NMR
(400 MHz, MeOD): δ 8.28–8.11 (m, 1H), 6.92 (dt, J = 20.5, 4.7 Hz, 3H), 6.34–5.99 (m, 3H), 4.76 (s, 2H),
4.47 (s, 2H), 3.98 (ddd, J = 139.3, 60.2, 35.9 Hz, 3H), 2.14–1.45 (m, 7H), 0.92–0.68 (m, 4H); HRMS m/z
calcd for C26H28N8O4 516.5620; found 517.4097 (M+H).
(S)-1-(2-((1-(Cyclopropanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin-4-yl)-2-(2,3-Dihydrobenzofuran-
5-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (17d)
Compound 17d was obtained as a white solid by the same procedure as above. (40%); 1H NMR
(400 MHz, MeOD): δ 8.24–8.09 (m, 1H), 7.32 (s, 1H), 7.19 (d, J = 7.8 Hz, 1H), 6.78 (d, J = 8.1 Hz, 1H),
6.17 (d, J = 77.2 Hz, 1H), 4.77 (s, 2H), 4.61 (t, J = 8.8 Hz, 2H), 4.48 (d, J = 2.8 Hz, 2H), 4.26–3.52 (m, 3H),
3.23 (dd, J = 10.2, 8.0 Hz, 2H), 2.19–1.43 (m, 6H), 1.31 (dd, J = 12.7, 5.3 Hz, 1H), 0.81 (ddd, J = 94.9, 52.5,
36.9 Hz, 4H); HRMS m/z calcd for C27H30N8O3 514.5900; found 515.4652 (M+H).
(R)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(3,4-Dichlorophenyl)- 4,6-
Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (18a)
Compound 18a was obtained as a white solid by the same procedure as above. (21%); 1H NMR
(400 MHz, MeOD): δ 8.29 (dd, J = 10.5, 5.3 Hz, 1H), 7.72 (t, J = 1.8 Hz, 1H), 7.61 (dd, J = 8.3, 2.0 Hz, 1H),
7.42–7.38 (m, 1H), 6.30 (s, 1H), 4.78 (d, J = 3.0 Hz, 2H), 4.50 (s, 2H), 3.90–3.42 (m, 4H), 2.30–1.71 (m, 4H), 0.87
(ddd, J = 10.2, 7.3, 3.4 Hz, 4H); HRMS m/z calcd for C24H24Cl2N8O2 527.4100; found 528.3486 (M+H).
(R)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(Naphthalen-2-yl) -4,6
-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (18b)
Compound 18b was obtained as a white solid by the same procedure as above. (37%); 1H NMR
(400 MHz, MeOD): δ 8.26–8.12 (m, 1H), 8.06 (d, J = 3.9 Hz, 1H), 7.96–7.85 (m, 3H), 7.62–7.46 (m, 3H),
6.24 (s, 1H), 4.82 (d, J = 2.4 Hz, 2H), 4.53 (t, J = 3.0 Hz, 2H), 3.99–3.41 (m, 4H), 1.86 (dt, J = 102.9, 33.3 Hz,
4H), 0.96–0.70 (m, 4H); HRMS m/z calcd for C28H28N8O2 508.5860; found 509.4154 (M+H).
(R)-2-(Benzo[d][1,3]Dioxol-5-yl)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4- yl)
-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (18c)
Compound 18c was obtained as a white solid by the same procedure as above. (13%); 1H NMR
(400 MHz, MeOD):
δ 8.21 (dd, J = 11.0, 5.4 Hz, 1H), 6.97 (tt, J = 3.1, 1.4 Hz, 2H), 6.90 (d, J = 8.5 Hz,
1H), 6.18 (s, 1H), 6.04 (dd, J = 2.5, 1.3 Hz, 2H), 4.78 (s, 2H), 4.49 (d, J = 3.0 Hz, 2H), 3.93–3.39 (m, 5H),
2.40–1.73 (m, 3H), 0.87 (dddd, J = 12.5, 9.8, 5.8, 2.2 Hz, 4H); HRMS m/z calcd for C25H26N8O4 502.5350;
found 503.4016 (M+H).
(R)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(2,3-Dihydrobenzofuran-
5-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (18d)
Compound 18d was obtained as a white solid by the same procedure as above. (40%); 1H NMR
(400 MHz, MeOD): δ 8.17 (dd, J = 12.3, 5.4 Hz, 1H), 7.33 (dd, J = 5.0, 1.3 Hz, 1H), 7.19 (d, J = 8.3 Hz, 1H),
6.79 (dd, J = 8.3, 1.6 Hz, 1H), 6.13 (s, 1H), 4.77 (s, 2H), 4.61 (td, J = 8.8, 2.0 Hz, 2H), 4.48 (d, J = 2.8 Hz,
2H), 4.37 (s, 1H), 3.83 (dddd, J = 29.1, 23.2, 18.4, 16.3 Hz, 2H), 3.68–3.38 (m, 2H), 3.23 (t, J = 8.7 Hz, 2H),
2.36–1.95 (m, 2H), 1.87–1.71 (m, 1H), 0.97–0.76 (m, 4H); HRMS m/z calcd for C26H28N8O3 500.5630;
found 501.4210 (M+H).
(S)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(3,4-Dichlorophenyl)-4,6-
Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (19a)

Int. J. Mol. Sci. 2020, 21, 1698
14 of 17
Compound 19a was obtained as a white solid by the same procedure as above. (35%); 1H NMR
(400 MHz, MeOD): 8.29 (dd, J = 10.6, 5.3 Hz, 1H), 7.72 (t, J = 1.8 Hz, 1H), 7.61 (dd, J = 8.3, 2.0 Hz, 1H),
δ
7.42–7.37 (m, 1H), 6.31 (s, 1H), 4.77 (d, J = 2.9 Hz, 2H), 4.50 (s, 2H), 3.92–3.46 (m, 4H), 2.30–1.68 (m, 4H),
0.93–0.81 (m, 4H); HRMS m/z calcd for C24H24Cl2N8O2 527.4100; found 528.3846 (M+H).
(S)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(3,4-Dichlorophenyl)-4,6-
Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (19b)
Compound 19b was obtained as a white solid by the same procedure as above. (27%); 1H NMR
(400 MHz, MeOD):
δ 8.25–8.13 (m, 1H), 8.09–8.04 (m, 1H), 7.97–7.86 (m, 3H), 7.64–7.47 (m, 3H), 6.24 (s,
1H), 4.82 (d, J = 2.4 Hz, 2H), 4.53 (t, J = 2.9 Hz, 2H), 3.91–3.40 (m, 4H), 2.14–1.50 (m, 4H), 0.93–0.76 (m,
4H); HRMS m/z calcd for C28H28N8O2 508.5860; found 509.4514 (M+H).
(S)-2-(Benzo[d][1,3]Dioxol-5-yl)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)
-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (19c)
Compound 19c was obtained as a white solid by the same procedure as above. (34%); 1H NMR
(400 MHz, MeOD):
δ 8.21 (dd, J = 11.0, 5.4 Hz, 1H), 7.01–6.95 (m, 2H), 6.90 (d, J = 8.5 Hz, 1H), 6.21
(d, J = 29.0 Hz, 1H), 6.07–6.02 (m, 2H), 4.78 (s, 2H), 4.48 (t, J = 3.0 Hz, 2H), 4.35 (s, 1H), 4.02–3.73 (m,
2H), 3.61–3.41 (m, 2H), 2.36–2.05 (m, 2H), 1.80 (dddd, J = 28.7, 12.7, 7.9, 4.7 Hz, 1H), 0.92–0.77 (m, 4H);
HRMS m/z calcd for C25H26N8O4 502.5350; found 503.4160 (M+H).
(S)-1-(2-((1-(Cyclopropanecarbonyl)Pyrrolidin-3-yl)Amino)Pyrimidin-4-yl)-2-(2,3-Dihydrobenzofuran
-5-yl)-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (19d)
Compound 19d was obtained as a white solid by the same procedure as above. (30%); 1H NMR
(400 MHz, MeOD):
δ 8.18 (dd, J = 12.2, 5.4 Hz, 1H), 7.34 (d, J = 3.8 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 6.79
(dd, J = 8.3, 1.6 Hz, 1H), 6.13 (s, 1H), 4.78 (s, 2H), 4.61 (td, J = 8.8, 2.0 Hz, 2H), 4.48 (s, 2H), 4.38 (s, 1H),
4.07–3.69 (m, 2H), 3.65–3.38 (m, 2H), 3.23 (t, J = 8.7 Hz, 2H), 2.36–1.95 (m, 2H), 1.79 (dddd, J = 29.6, 12.7,
7.9, 4.7 Hz, 1H), 0.96–0.77 (m, 4H); HRMS m/z calcd for C26H28N8O3 500.5630; found 501.2041 (M+H).
(S)-1-(2-((1-(Cyclobutanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin-4-yl)-2-(3,4-Dichlorophenyl)-4,6-
Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (20a)
Compound 20a was obtained as a white solid by the same procedure as above. (24%); 1H NMR
(400 MHz, MeOD): δ 8.40–8.22 (m, 1H), 7.71 (d, J = 15.5 Hz, 1H), 7.61 (dd, J = 8.3, 4.8 Hz, 1H), 7.43–7.35 (m,
1H), 6.39 (d, J = 97.2 Hz, 1H), 4.81 (s, 2H), 4.50 (dd, J = 12.3, 2.9 Hz, 2H), 3.68 (s, 1H), 3.53–3.39 (m, 1H),
3.03 (d, J = 16.4 Hz, 1H), 2.91 (dd, J = 18.5, 8.5 Hz, 1H), 2.42–2.17 (m, 4H), 2.12–1.98 (m, 2H), 1.91–1.71 (m,
3H), 1.66–1.41 (m, 3H).; HRMS m/z calcd for C26H28Cl2N8O2 555.4640; found 556.4531 (M+H).
(S)-2-(Benzo[d][1,3]Dioxol-5-yl)-1-(2-((1-(Cyclobutanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin-4-yl)
-4,6-Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (20c)
Compound 20c was obtained as a white solid by the same procedure as above. (29%); 1H NMR
(400 MHz, MeOD):
δ 8.28–8.14 (m, 1H), 7.03–6.83 (m, 3H), 6.20 (d, J = 61.5 Hz, 3H), 4.80 (s, 2H), 4.48 (s,
2H), 4.06 (d, J = 81.6 Hz, 2H), 3.13–3.02 (m, 1H), 2.94 (s, 1H), 2.15–1.43 (m, 12H); HRMS m/z calcd for
C27H30N8O4 530.5890; found 531.2490 (M+H).
(S)-1-(2-((1-(Cyclopentanecarbonyl)Piperidin-3-yl)Amino)Pyrimidin-4-yl)-2-(3,4-Dichlorophenyl)-4,6-
Dihydropyrrolo[3,4-d]Imidazole-5(1H)-Carboxamide (21a)
Compound 21a was obtained as a white solid by the same procedure as above. (68%); 1H NMR
(400 MHz, MeOD):
δ 8.38–8.24 (m, 1H), 7.71 (d, J = 10.9 Hz, 1H), 7.60 (d, J = 8.3 Hz, 1H), 7.42–7.34 (m,
1H), 6.36 (d, J = 86.1 Hz, 1H), 4.82 (s, 2H), 4.52 (d, J = 9.3 Hz, 2H), 4.21 (s, 1H), 3.97 (d, J = 35.3 Hz, 1H),
3.26–3.04 (m, 2H), 2.87 (s, 2H), 2.06–1.56 (m, 12H); HRMS m/z calcd for C27H30Cl2N8O2 569.4910;
found 570.3722 (M+H).

Int. J. Mol. Sci. 2020, 21, 1698
15 of 17
3.1.16. General Synthesis of (S)-(1-(2-((1-(Cyclopropanecarbonyl)piperidin-3-yl)amino)pyrimidin
-4-yl)-2-(3,4-dichlorophenyl)-4,6- dihydropyrrolo[3,4-d]Imidazol-5(1H)-yl)(4-hydroxypiperidin
-1-yl)methanone (22a)
Compound 11a (0.05 mol) was dissolved in 0.5 mL of 1,4-dioxane, and 0.25 mL of 4 M HCl
in 1,4-dioxane was added. The mixture was stirred at ambient temperature for 1 h 30 min. After
concentrating 1,4-dioxane in vacuo, compound 16 was obtained. Compound 16 (0.044 mmol) was
dissolved in 0.44 mL of 1,4-dioxane and treated with 4-nitrophenyl chloroformate (0.044 mmol) and
dimethylformamide (0.22 mL) and stirred at ambient temperature for 1 h. 4-Piperidinol (0.22 mmol)
was added and stirred at ambient temperature for 48 h. We concentrated the 1,4-dioxane in vacuo,
extracted with ethyl acetate, and washed with water and brine. Drying over anhydrous magnesium
sulfate, the solvent was concentrated in vacuo and the product purified using column chromatography
on silica gel using a mobile phase of MC: MeOH (10: 1) to afford compound 22a as a white solid. (16%);
1H NMR (400 MHz, MeOD):
δ 8.27 (dd, J = 17.3, 5.0 Hz, 1H), 7.70 (d, J = 1.9 Hz, 1H), 7.60 (d, J = 8.2 Hz,
1H), 7.38 (s, 1H), 6.29 (s, 1H), 4.95 (s, 2H), 4.58 (t, J = 11.4 Hz, 2H), 4.35 (s, 1H), 4.10 (dd, J = 14.3, 7.1 Hz,
1H), 3.82 (ddd, J = 12.9, 8.6, 3.9 Hz, 1H), 3.71 (d, J = 13.7 Hz, 2H), 3.45 (d, J = 28.8 Hz, 1H), 3.00 (dd,
J = 66.0, 53.2 Hz, 4H), 1.90 (dd, J = 42.4, 32.4 Hz, 5H), 1.55 (td, J = 12.9, 3.6 Hz, 4H), 0.83 (dd, J = 32.6,
25.9 Hz, 4H); HRMS m/z calcd for C30H34Cl2N8O3 625.5550; found 626.4741 (M+H).
3.2. Molecular Modeling
Compounds were docked into the JNK3 structure (PDB: 3OY1). Protein and ligand preparations
were performed with the Schrödinger Maestro program (New York, NY, USA) with standard settings,
and Glide was used for docking and scoring. The 3D X-ray protein structures of JNK3 as a complex with
a ligand were obtained from the PDB (code: 3OY1) and prepared using the Protein Preparation Wizard
of the Schrödinger Maestro program. All water molecules were removed from the structure, and it
was selected as a template. The structures of inhibitors were drawn using ChemDraw (Seoul, Korea),
and their 3D conformations were generated using the Schrödinger LigPrep program with the OPLS
2005 force field (New York, NY, USA). Molecular dockings of compounds into the structure of JNK3
(PDB code: 3OY1) were carried out using Schrodinger Glide (Version 12.2).
3.3. Evaluation of IC50 Values and Selected Kinase Profiling
We used Reaction Biology Corp.’s Kinase HotSpotSM service (www.reactionbiology.com) for IC50
determination of all compounds and kinase profiles. Assay protocol: in a final reaction volume of
25
µL, ATF, 5
µM, ATP 10
µM, and JNK3 (h) (5–10 mU) were incubated with 25 mM Tris (pH 7.5),
0.02 mM EGTA, 0.66 mg/mL myelin basic protein, 10 mM Mg acetate, and [
γ
-33P-ATP] (specific activity
approx. 500 cpm/pmol, concentration as required). The reaction was initiated by the addition of the
Mg-ATP mix. After incubation for 40 min at room temperature, the reaction was stopped by the
addition of 5 µL of a 3% phosphoric acid solution. Then, 10 µL of the reaction was spotted onto a P30
filtermat and washed three times for 5 min in 75 mM phosphoric acid and once in methanol prior to
drying and scintillation counting.
4. Conclusions
We successfully synthesized 1-pyrimidinyl-2-aryl-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)
-carboxamide derivatives that were designed as novel JNK3 inhibitors with better inhibitory activity
than the previous lead in an effort to maintain the main interactions identified through the previous
docking study [14]. Sixteen compounds were synthesized and measured for their enzyme activity
against JNK3. In particular, compounds 17a, 18a, 17b, and 18b showed competitive activities against
JNK3 with IC50 values of 10.4 nM, 2.69 nM, 4.81 nM, and 4.52 nM, respectively. Compound 18a
was, indeed, a selective JNK3 inhibitor with an excellent selectivity profile, especially compared to
its activity against similar protein kinases such as p38α, Erk, and JNK1. We believe that this novel
scaffold of 1-pyrimidinyl-2-aryl-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide derivatives

Int. J. Mol. Sci. 2020, 21, 1698
16 of 17
will be highly useful in the development of JNK3-selective inhibitors as therapeutic agents for
neurodegenerative diseases.
Author Contributions: Conceptualization, J.-M.H.; methodology, M.J., Y.O., S.Y., H.M., D.I. and J.-M.H.; software,
H.C.; writing—original draft preparation, M.J., and J.-M.H.; writing—review and editing, J.-M.H.; funding
acquisition, J.-M.H. All authors have read and agreed to the published version of the manuscript.
Funding: This work was financially supported by a National Research Foundation of Korea grant
(NRF-2017R1A2B4006447 and NRF-2019M3A9A8066500; J.-M.H.).
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
Ahn, J.-H.; So, S.-P.; Kim, N.-Y.; Kim, H.-J.; Yoon, S.-Y.; Kim, D.-H. c-Jun N-terminal Kinase (JNK) induces
phosphorylation of amyloid precursor protein (APP) at Thr668, in okadaic acid-induced neurodegeneration.
BMB Rep. 2016, 49, 376–381. [CrossRef]
2.
3.
4.
5.
6.
Yarza, R.; Vela, S.; Solas, M.; Ramirez, M.J. c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target
for Alzheimer’s Disease. Front. Pharmacol. 2016, 6, 321.
Yamasaki, T.; Kawasaki, H.; Nishina, H. Diverse Roles of JNK and MKK Pathways in the Brain.
J. Signal Transduct. 2012, 2012, 1–9. [CrossRef] [PubMed]
Spencer, J.P.E. The interactions of flavonoids within neuronal signalling pathways. Genes Nutr. 2007, 2,
257–273. [PubMed]
Bogoyevitch, M.A.; Ngoei, K.R.; Zhao, T.T.; Yeap, Y.Y.C.; Ng, D.C.H. c-Jun N-terminal kinase (JNK) signaling:
Recent advances and challenges. Biochim. Biophys. Acta 2010, 1804, 463–475. [CrossRef] [PubMed]
Chambers, J.W.; Pachori, A.; Howard, S.; Iqbal, S.; LoGrasso, P.V. Inhibition of JNK mitochondrial localization
and signaling is protective against ischemia/reperfusion injury in rats. J. Biol. Chem. 2013, 288, 4000–4011.
[CrossRef] [PubMed]
7.
8.
9.
Haeusgen, W.; Boehm, R.; Zhao, Y.; Herdegen, T.; Waetzig, V. Specific activities of individual c-Jun N-terminal
kinases in the brain. Neuroscience 2009, 161, 951–959. [CrossRef]
LoGrasso, P.; Kamenecka, T. Inhibitors of c-jun-N-terminal kinase (JNK). Mini-Rev. Med. Chem. 2008, 8,
755–766. [CrossRef]
Kyriakis, J.M.; Banerjee, P.; Nikolakaki, E.; Dai, T.; Rubie, E.A. The stress-activated protein kinase subfamily
of c-Jun kinases. Nature 1994, 369, 156–160. [CrossRef]
10. Kim, E.K.; Choi, E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys.
Acta Mol. Basis Dis. 2010, 1802, 396–405. [CrossRef]
11. Salh, B. c-Jun N-terminal kinases as potential therapeutic targets. Expert Opin. Ther. Targets 2007, 11,
1339–1353. [CrossRef] [PubMed]
12. Mazzitelli, S.; Xu, P.; Ferrer, I.; Davis, R.J.; Tournier, C. The Loss of c-Jun N-Terminal Protein Kinase Activity
Prevents the Amyloidogenic Cleavage of Amyloid Precursor Protein and the Formation of Amyloid Plaques
In Vivo. J. Neurosci. 2011, 31, 16969–16976. [CrossRef] [PubMed]
13. Yoon, S.O.; Park, D.J.; Ryu, J.C.; Ozer, H.G.; Tep, C.; Shin, Y.J.; Lim, T.H.; Pastorino, L.; Kunwar, A.J.;
Walton, J.C.; et al. JNK3 perpetuates metabolic stress induced by Abeta peptides. Neuron 2012, 75, 824–837.
[CrossRef]
14. Yoshida, H.; Hastie, C.J.; McLauchlan, H.; Cohen, P.; Goedert, M. Phosphorylation of microtubule-associated
protein tau by isoforms of c-Jun N-terminal kinase (JNK). J. Neurochem. 2004, 90, 352–358. [CrossRef]
[PubMed]
15. Kim, M.; Lee, J.; Hah, J.M.; Kim, M.; Park, Y.-J.; Ahn, H.; Kwon, Y.H.; Hah, J.-M. Syntheses and biological
evaluation of 1-heteroaryl-2-aryl-1 H -benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with
neuroprotective effects. Bioorganic Med. Chem. 2013, 21, 2271–2285. [CrossRef]
16. Vivanco, I.; Palaskas, N.; Tran, C.; Finn, S.P.; Getz, G.; Kennedy, N.J.; Jiao, J.; Rose, J.; Xie, W.; Loda, M.;
et al. Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN.
Cancer Cell 2007, 11, 555–569. [CrossRef]

Int. J. Mol. Sci. 2020, 21, 1698
17 of 17
17. Szczepankiewicz, B.G.; Kosogof, C.; Nelson, L.T.J.; Liu, G.; Liu, B.; Zhao, H.; Serby, M.D.; Xin, Z.; Liu, M.;
Gum, R.J.; et al. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal
cross-kinase activity. J. Med. Chem. 2006, 49, 3563–3580. [CrossRef]
18. Linkermann, A.; Green, D.R. Necroptosis. N. Engl. J. Med. 2014, 370, 455–465. [CrossRef]
19. Vandenabeele, P.; Galluzzi, L.; Vanden Berghe, T.; Kroemer, G. Molecular mechanisms of necroptosis:
An ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 2010, 11, 700–714. [CrossRef]
20. Jha, N.K.; Jha, S.K.; Kar, R.; Nand, P.; Swati, K.; Goswami, V.K. Nuclear factor-kappa
β as a therapeutic target
for Alzheimer’s disease. J. Neurochem. 2019, 150, 113–137. [CrossRef]
21. Caccamo, A.; Branca, C.; Piras, I.S.; Ferreira, E. Necroptosis activation in Alzheimer’s disease. Nat. Neurosci.
2017, 20, 1236–1246. [CrossRef] [PubMed]
22. TurabNaqvi, A.A.; Hasan, G.M.; Hassan, M.I. Targeting tau hyperphosphorylation via kinase inhibition-
Strategy to address Alzheimers’ disease. Curr. Top. Med. Chem. 2020, 20. [CrossRef] [PubMed]
23. Das, T.K.; Jana, P.; Chakrabarti, S.K.; Abdul Hamid, M.R.W. Curcumin Downregulates GSK3 and Cdk5
in Scopolamine-Induced Alzheimer’s Disease Rats Abrogating Aβ40/42 and Tau Hyperphosphorylation.
J. Alzheimer’s Dis. Rep. 2019, 3, 257–267. [CrossRef] [PubMed]
24. Reaction Biology Corp. Kinase HotSpotSM service was used for screening of 18a. Available online:
www.reactionbiology.com (accessed on 3 December 2019).
©
2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).